Adherence in the Treatment of Inflammatory Bowel Disease With Particular Focus on the Importance of the Clinical Pharmacist: A Systematic Review

Background The prevalence of inflammatory bowel disease (IBD) is increasing. While several studies have shown that incorporating a clinical pharmacist into patient care can improve quality of life, evidence specifically addressing their role in IBD management remains limited. Objectives This study aimed to systematically review the evidence on treatment adherence in IBD, with a focus on the potential role of clinical pharmacist counselling to improve medication adherence. Methods Three databases (PubMed, MEDLINE and Embase) were searched to identify relevant literature, using keywords derived from the PICO model. Results Seven full‐text articles met the inclusion criteria. Three of these reported that pharmacist involvement had a positive effect on treatment adherence in patients with IBD. Furthermore, two studies reported that pharmacist involvement in treatment improved disease activity. Patients' perceptions of pharmacist involvement were generally positive, particularly after receiving information about pharmacist services and education. Finally, studies also indicate that pharmacists require greater knowledge of IBD to provide optimal care. Conclusion Although the available literature is limited, it indicates that involving clinical pharmacists in IBD treatment may have a positive impact—improving medication adherence and enhancing disease control.